Oncologic Outcomes of Laparoscopic Radical Prostatectomy: Intermediate-Term Follow- up  Fernando P. Secin, Fernando J. Bianco, Nicholas T. Karanikolas, Karim Touijer, Bertrand Guillonneau  European Urology Supplements  Volume 5, Issue 19, Pages 934-941 (November 2006) DOI: 10.1016/j.eursup.2006.08.001 Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 1 The cumulative 5-yr biochemical recurrence-free rate for 1001 patients. European Urology Supplements 2006 5, 934-941DOI: (10.1016/j.eursup.2006.08.001) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 2 Scatter plots of preoperative (A) and postoperative nomograms over time (B), showing that there has not been a clear stage migration or selection of patients over time. European Urology Supplements 2006 5, 934-941DOI: (10.1016/j.eursup.2006.08.001) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 3 Bar chart shows the proportion of patients with pT3 or pT4 disease in comparison to pT2 grouped in 100s of cases. European Urology Supplements 2006 5, 934-941DOI: (10.1016/j.eursup.2006.08.001) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 4 Univariate association between (A) pathologic Gleason, (B) serum prostate-specific antigen level, (C) positive surgical margin status, (D) seminal vesicle invasion, (E) lymph node status, and (F) pathologic stage and time to biochemical recurrence. The log-rank test is used to compare the Kaplan-Meier curves. European Urology Supplements 2006 5, 934-941DOI: (10.1016/j.eursup.2006.08.001) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 5 (A) Comparison of biochemical recurrence-free Kaplan-Meier curves between N0 and Nx disease among patients with low-risk disease, defined as prostate-specific antigen (PSA) level<10ng/ml and clinical stage T1c/T2a and biopsy Gleason score<7. (B) Comparison of the same features for patients with intermediate risk, defined by the presence of PSA level of 10–20ng/ml or clinical stage T2b or biopsy Gleason score 7. European Urology Supplements 2006 5, 934-941DOI: (10.1016/j.eursup.2006.08.001) Copyright © 2006 European Association of Urology Terms and Conditions

Fig. 6 Cumulative biochemical recurrence free rates of patients with extracapsular extension [ECE] (A) and/or seminal vesicle invasion [SVI] (B) with or without positive surgical margins [PSM]. European Urology Supplements 2006 5, 934-941DOI: (10.1016/j.eursup.2006.08.001) Copyright © 2006 European Association of Urology Terms and Conditions